Williams-Sonoma (WSM) CEO Laura Alber Sells Shares

What Happened
Laura Alber, President & CEO (and director) of Williams‑Sonoma, sold a total of 35,000 shares of WSM stock in open‑market transactions on July 15, 2026, generating aggregate proceeds of $7,747,894 (~$7.75M). The sales were reported in five groups with the following weighted average prices and proceeds:

• 1,000 shares @ $219.10 = $219,100 (per‑share range $218.47–$219.42)
• 8,553 shares @ $220.02 = $1,881,831 (range $219.51–$220.49)
• 5,190 shares @ $220.92 = $1,146,575 (range $220.50–$221.49)
• 16,894 shares @ $222.05 = $3,751,313 (range $221.53–$222.51)
• 3,363 shares @ $222.74 = $749,075 (range $222.53–$222.95)
  These sales were executed pursuant to a Rule 10b5‑1 trading plan adopted by Ms. Alber on October 2, 2025. Sales are generally viewed as routine divestiture activity rather than a bullish signal.

Key Details

• Transaction date: July 15, 2026 (filed on July 17, 2026) — filing appears to be within the typical 2‑business‑day Form 4 window.
• Aggregate shares sold: 35,000; aggregate proceeds: $7,747,894 (~$7.75M).
• Price info: weighted averages shown above; per‑share prices within the ranges listed for each group (the filing notes the reporter will provide per‑price breakdown on request).
• Footnotes: F1 = sales pursuant to a 10b5‑1 plan (adopted Oct 2, 2025). F2–F6 = indicate per‑share price ranges for each sale group and willingness to provide detailed breakdown if requested. F7 = references holdings in the Williams‑Sonoma, Inc. 401(k) Stock Fund as of July 15, 2026 (specific 401(k) share count not included in the excerpt).
• Filing timeliness: Reported July 17 for trades on July 15; this appears timely under the standard 2‑business‑day rule.

Context

• Sales under a Rule 10b5‑1 plan are typically pre‑arranged and executed according to a predetermined schedule or formula; they reduce the ability to infer immediate managerial views about the stock.
• For retail investors, purchases are generally more informative about insider confidence; routine sales (especially under 10b5‑1 plans) are common for diversification or tax planning.
• No option exercises, gifts, or award grants were reported in this filing.